Disc Medicine Announces First Patient Enrolled in Phase 1/2 Clinical Trial of Bitopertin in Diamond-Blackfan Anemia (DBA)
WATERTOWN, Mass., July 27, 2023 (GLOBE NEWSWIRE) — Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical…
Month: July 2023
Disc Medicine Announces First Patient Enrolled in Phase 1/2 Clinical Trial of Bitopertin in Diamond-Blackfan Anemia (DBA)
WATERTOWN, Mass., July 27, 2023 (GLOBE NEWSWIRE) — Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical…
Celularity and Verséa Ophthalmics Announce Exclusive U.S. Commercialization Agreement to Distribute Biovance® and Biovance® 3l Ocular For Ophthalmic Applications
FLORHAM PARK, N.J. and TAMPA, Fla., July 27, 2023 (GLOBE NEWSWIRE) — Celularity Inc. (Nasdaq:…
Celularity and Verséa Ophthalmics Announce Exclusive U.S. Commercialization Agreement to Distribute Biovance® and Biovance® 3l Ocular For Ophthalmic Applications
FLORHAM PARK, N.J. and TAMPA, Fla., July 27, 2023 (GLOBE NEWSWIRE) — Celularity Inc. (Nasdaq:…
Sorrento Issues a “FAQ” in Response to Large Number Of Urgent Requests from Scilex Dividend Short Holders and/or Record Holders
SAN DIEGO, July 27, 2023 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (OTC: SRNEQ, “Sorrento”), a…
Sorrento Issues a “FAQ” in Response to Large Number Of Urgent Requests from Scilex Dividend Short Holders and/or Record Holders
SAN DIEGO, July 27, 2023 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (OTC: SRNEQ, “Sorrento”), a…
Femasys Announces Notice of Allowance for New U.S. Patent Application Covering Use of FemBloc for Female Permanent Birth Control
FemBloc® patent application provides additional coverage for Femasys’ therapeutic option for women seeking permanent birth…
Femasys Announces Notice of Allowance for New U.S. Patent Application Covering Use of FemBloc for Female Permanent Birth Control
FemBloc® patent application provides additional coverage for Femasys’ therapeutic option for women seeking permanent birth…
Avenue Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy’s Disease)
Topline data expected in 2024 MIAMI, July 27, 2023 (GLOBE NEWSWIRE) — Avenue Therapeutics, Inc….
Avenue Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy’s Disease)
Topline data expected in 2024 MIAMI, July 27, 2023 (GLOBE NEWSWIRE) — Avenue Therapeutics, Inc….
Wave Life Sciences Second Quarter 2023 Financial Results Scheduled for August 3, 2023
CAMBRIDGE, Mass., July 27, 2023 (GLOBE NEWSWIRE) — Wave Life Sciences Ltd. (Nasdaq: WVE), a…
Wave Life Sciences Second Quarter 2023 Financial Results Scheduled for August 3, 2023
CAMBRIDGE, Mass., July 27, 2023 (GLOBE NEWSWIRE) — Wave Life Sciences Ltd. (Nasdaq: WVE), a…
Ayala Pharmaceuticals and Biosight Enter into Definitive Merger Agreement
Combined company to operate as Ayala Pharmaceuticals, Inc. Merger to add a clinical stage oncology…
Ayala Pharmaceuticals and Biosight Enter into Definitive Merger Agreement
Combined company to operate as Ayala Pharmaceuticals, Inc. Merger to add a clinical stage oncology…
Avalyn Pharma Invited to Present at Canaccord Genuity Annual Growth Conference
SEATTLE , July 27, 2023 (GLOBE NEWSWIRE) — Avalyn Pharma Inc., a clinical-stage biopharmaceutical company…
Avalyn Pharma Invited to Present at Canaccord Genuity Annual Growth Conference
SEATTLE , July 27, 2023 (GLOBE NEWSWIRE) — Avalyn Pharma Inc., a clinical-stage biopharmaceutical company…
Biora Therapeutics Announces Clinical Device Performance Study Results for its NaviCap™ Targeted Oral Delivery Platform
Phase 1-ready device shows 100% success in human functional study of twelve subjects to date…
Biora Therapeutics Announces Clinical Device Performance Study Results for its NaviCap™ Targeted Oral Delivery Platform
Phase 1-ready device shows 100% success in human functional study of twelve subjects to date…
Telavant, a Roivant Company, Advances Inflammatory Bowel Disease Program with First Patient Dosed in Global Phase 2 Trial of Novel Anti-TL1A Antibody RVT-3101 in Crohn’s Disease
The Phase 2 TAHOE study, which is currently enrolling, evaluates the safety and efficacy of…
Telavant, a Roivant Company, Advances Inflammatory Bowel Disease Program with First Patient Dosed in Global Phase 2 Trial of Novel Anti-TL1A Antibody RVT-3101 in Crohn’s Disease
The Phase 2 TAHOE study, which is currently enrolling, evaluates the safety and efficacy of…